On July 28, Ascletis Pharmaceuticals-B (01672) issued an announcement, announcing that the first batch of obese or overweight subjects have been dosed in the 12-week Phase IIa study of its small molecule GLP-1R agonist ASC30 once-monthly subcutaneous reservoir formulation in the United States. The study targets obese people or overweight people with at least one weight-related comorbidity. Preliminary results show that the half-life of ASC30 is as long as 36 days, supporting the once-monthly dosing regimen. The results of the Phase Ib study showed that compared with the trough concentration of ASC30 on the 29th day, the peak-to-trough ratio of the blood drug concentration of this ultra-long-acting subcutaneous reservoir formulation was less than 2:1, meeting the requirements of good tolerability.

The company expects to obtain top-line data from a 12-week Phase IIa study of ASC30's monthly subcutaneous depot formulation in the first quarter of 2026. ASC30 is the first small molecule GLP-1R-biased agonist for the treatment of obesity that is suitable for both daily oral administration and monthly subcutaneous injection. It has compound patent protection in the United States and around the world, with patent protection until 2044 (excluding patent extensions).

Source：https://finance.eastmoney.com/a/202507283468940217.html